Stomach Cancer ED
- A blood-based test for diagnosis of gastric cancer by detecting a combination of proprietary epigenomics DNA methylation biomarkers.
0
People watching this product now!
- Sensitivity 80.77%
- Specificity 92.07%
- A blood-based test for diagnosis of gastric cancer by detecting a combination of proprietary epigenomics DNA methylation biomarkers.
- Detection of early gastric cancer & precancerous lesions.
- Patients with a positive test result should be referred for diagnostic
- Patients with a negative test result should discuss with their doctor when they need to be tested again.
- Follow-up and monitoring.
- Prognostic evaluation.
- Therapeutic assessment.
- Tumor markers, like CEA and CA-199, low sensitivity.
- Gastroscope, invasive with low follow-up rate.
- PG and G17, low specificity.
- Male & female aged 40 and above.
- A history of gastric cancer in first degree relatives.
- Been diagnosed with other gastric precancerous disease(s), like chronic atrophic gastritis (CAG), gastric ulcer, gastric polyps, residual stomach, hypertrophic gastritis, or pernicious anemia.
- Helicobacter pylori infection
- Areas with a high incidence of gastric cancer, other risk factors of gastric cancer (eg.high salt intake, pickled diet, smoking, drinking).
